A Phase 2 Study of Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma

This study focuses on a treatment for Mantle Cell Lymphoma, a type of cancer that affects the lymph system. The treatment being tested is a drug called Enzastaurin HCl, which is taken orally. The study aims to understand if this drug is safe for patients who have experienced a relapse of Mantle Cell Lymphoma. It also seeks to identify any potential side effects associated with the drug and evaluate its effectiveness in helping patients manage their condition. During the study, participants will be given Enzastaurin HCl to take orally. The primary outcome measured is the percentage of participants who show 'Freedom From Progression' (FFP) for at least 3 cycles. This means that the participants' condition does not worsen during this period. To determine this, the study uses the Standardized Response Criteria for non-Hodgkin's lymphomas. If a participant shows a 50% increase in the size of their affected lymph nodes or if new affected sites appear, they are considered to have progressive disease. The percentage of FFP is then calculated by dividing the number of participants who are progression-free after 3 cycles of treatment by the total number of treated participants and multiplying the result by 100.